The DOI matches its Crossref record, with a small difference in title or year; 229 of the 229 references it cites were found in a registry or an index.
Towards a glutamate hypothesis of depression
Open accessAbstract
Half a century after the first formulation of the monoamine hypothesis, compelling evidence implies that long-term changes in an array of brain areas and circuits mediating complex cognitive-emotional behaviors represent the biological underpinnings of mood/anxiety disorders. A large number of clinical studies suggest that pathophysiology is associated with dysfunction of the predominant glutamatergic system, malfunction in the mechanisms regulating clearance and metabolism of glutamate, and cytoarchitectural/morphological maladaptive changes in a number of brain areas mediating cognitive-emotional behaviors. Concurrently, a wealth of data from animal models have shown that different types of environmental stress enhance glutamate release/transmission in limbic/cortical areas and exert powerful structural effects, inducing dendritic remodeling, reduction of synapses and possibly volumetric reductions resembling those observed in depressed patients. Because a vast majority of neurons and synapses in these areas and circuits use glutamate as neurotransmitter, it would be limiting to maintain that glutamate is in some way 'involved' in mood/anxiety disorders; rather it should be recognized that the glutamatergic system is a primary mediator of psychiatric pathology and, potentially, also a final common pathway for the therapeutic action of antidepressant agents. A paradigm shift from a monoamine hypothesis of depression to a neuroplasticity hypothesis focused on glutamate may represent a substantial advancement in the working hypothesis that drives research for new drugs and therapies. Importantly, despite the availability of multiple classes of drugs with monoamine-based mechanisms of action, there remains a large percentage of patients who fail to achieve a sustained remission of depressive symptoms. The unmet need for improved pharmacotherapies for treatment-resistant depression means there is a large space for the development of new compounds with novel mechanisms of action such as glutamate transmission and related pathways. This article is part of a Special Issue entitled 'Anxiety and Depression'.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Serotonin modulates glutamatergic transmission and might kindle N-methyl-D-aspartate (NMDA) receptor dependent plasticity (Bennett, 2010;Sanacora et al., 2012).”
From Serotonin and neuroplasticity – Links between molecular, functional and structural pathophysiology in depression (2017) · cites this paper as Sanacora et al., 2012
Experimental — accuracy not yet measuredIn the citing paper
“There are three broad disease models proposed by the literature to explain treatment resistance, summarised in Figure 5 (see eAppendix 3 for search details). 48–51”
From Treatment resistance in psychiatry: state of the art and new directions (2022) · cites this paper as [50]
In the citing paper
“There has been suggestion that glutamatergic neurotransmission is dysregulated in MDD.83,84”
From Ketamine as an antidepressant: Overview of its mechanisms of action and potential predictive biomarkers (2020) · cites this paper as [83]
In the citing paper
“Stress-induced dysfunction in forebrain excitatory transmission has led to the development of the excitatory synaptic transmission hypothesis of depression (22, 32, 33).”
From Emerging Role for Nucleus Accumbens Medium Spiny Neuron Subtypes in Depression (2017) · cites this paper as [32]
In the citing paper
“Interestingly, antidepressants are believed to exert one of the therapeutic effects by modulating the extracellular availability of this neurotransmitter [122,123,124,125].”
From P2X7 Receptor Signaling in Stress and Depression (2019) · cites this paper as [123]
In the citing paper
“Altogether, there are substantial evidence that P2X7R modulates 5-HT, NA, glutamate, GABA and NO release, which are mechanisms consistently involved in stress and depression [123,129,130].”
From P2X7 Receptor Signaling in Stress and Depression (2019) · cites this paper as [123]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y., Jiang, Q. L., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,351
(1994) · DigitalGeorgetown (Georgetown University Library) · Cited by 10,542
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,526
DESCARTES' ERROR: Emotion, Reason, and the Human Brain
Marg, E. (1995) · Optometry and Vision Science · doi:10.1002/j.1538-9235.1995.tb03988.x · Cited by 8,178
Stress and the brain: from adaptation to disease
de Kloet, E. R., Joëls, M., & Holsboer, F. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1683 · Cited by 4,621
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941
Trivedi, M. H., Rush, A. J., Wisniewski, S. R., Nierenberg, A. A., Warden, D., Ritz, L., Norquist, G., Howland, R. H., Lebowitz, B., McGrath, P. J., et al. (2006) · American Journal of Psychiatry · doi:10.1176/appi.ajp.163.1.28 · Cited by 3,879
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
THE CATECHOLAMINE HYPOTHESIS OF AFFECTIVE DISORDERS: A REVIEW OF SUPPORTING EVIDENCE
Schildkraut, J. J. (1965) · American Journal of Psychiatry · doi:10.1176/ajp.122.5.509 · Cited by 3,568
Research works printed but not linked: 3
- Popoli, 2010, Acute behavioural stress affects the readily releasable pool of vesicles in prefrontal/frontal cortex, Soc. Neurosci.
- Yamamoto, 2006, The glutamatergic system in neuronal plasticity and vulnerability in mood disorders, Neuropsych. Dis. Treat., 2, 7
- Yuen, 2010, Repeated stress suppresses glutamate receptor expression and function in prefrontal cortex and impairs object recognition memory, Soc. Neurosci.
Cited by
Sorted by citations
The stressed synapse: the impact of stress and glucocorticoids on glutamate transmission
Popoli, M., Yan, Z., McEwen, B. S., & Sanacora, G. (2012) · Nature Reviews Neuroscience · doi:10.1038/nrn3138 · Cited by 1,393
Self-citationInflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications
Felger, J. C., & Lotrich, F. E. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.04.060 · Cited by 1,180
Neuroinflammation and depression: A review
Troubat, R., Barone, P., Leman, S., Desmidt, T., Cressant, A., Atanasova, B., Brizard, B., El Hage, W., Surget, A., Belzung, C., et al. (2021) · European Journal of Neuroscience · doi:10.1111/ejn.14720 · Cited by 1,107
Duman, R. S., Sanacora, G., & Krystal, J. H. (2019) · Neuron · doi:10.1016/j.neuron.2019.03.013 · Cited by 1,026
Self-citationManagement of Depression in Older Adults: A Review
Kok, R. M., & Reynolds, C. F. (2017) · JAMA · doi:10.1001/jama.2017.5706 · Cited by 890
Agudelo, L. Z., Femenía, T., Orhan, F., Porsmyr-Palmertz, M., Goiny, M., Martinez-Redondo, V., Correia, J. C., Izadi, M., Bhat, M., Schuppe-Koistinen, I., et al. (2014) · Cell · doi:10.1016/j.cell.2014.07.051 · Cited by 739
Neuroinflammation and psychiatric illness
Najjar, S., Pearlman, D. M., Alper, K., Najjar, A., & Devinsky, O. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-43 · Cited by 733
R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects
Yang, C., Shirayama, Y., Zhang, J.-C., Ren, Q., Yao, W., Ma, M., Dong, C., & Hashimoto, K. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.136 · Cited by 605
Neural Mechanisms of Stress Resilience and Vulnerability
Franklin, T. B., Saab, B. J., & Mansuy, I. M. (2012) · Neuron · doi:10.1016/j.neuron.2012.08.016 · Cited by 500
Lener, M. S., Niciu, M. J., Ballard, E. D., Park, M., Park, L. T., Nugent, A. C., & Zarate, C. A. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.05.005 · Cited by 468
Kraus, C., Castrén, E., Kasper, S., & Lanzenberger, R. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.03.007 · Cited by 471
Treatment resistance in psychiatry: state of the art and new directions
Howes, O. D., Thase, M. E., & Pillinger, T. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01200-3 · Cited by 413
Fried, E. I. (2015) · Frontiers in Psychology · doi:10.3389/fpsyg.2015.00309 · Cited by 367
Animal models of major depression and their clinical implications
Czéh, B., Fuchs, E., Wiborg, O., & Simon, M. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2015.04.004 · Cited by 375
Fee, C., Banasr, M., & Sibille, E. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.05.024 · Cited by 329
Weder, N., Zhang, H., Jensen, K., Yang, B. Z., Simen, A., Jackowski, A., Lipschitz, D., Douglas-Palumberi, H., Ge, M., Perepletchikova, F., et al. (2014) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2013.12.025 · Cited by 324
Microglial Dysregulation in Psychiatric Disease
Frick, L. R., Williams, K., & Pittenger, C. (2013) · Clinical and Developmental Immunology · doi:10.1155/2013/608654 · Cited by 299
Andrews, P. W., Bharwani, A., Lee, K. R., Fox, M., & Thomson, J. A. (2015) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2015.01.018 · Cited by 281
Cobb, J. A., O’Neill, K., Milner, J., Mahajan, G. J., Lawrence, T. J., May, W. L., Miguel-Hidalgo, J., Rajkowska, G., & Stockmeier, C. A. (2016) · Neuroscience · doi:10.1016/j.neuroscience.2015.12.044 · Cited by 254
Genome-wide analysis of over 106 000 individuals identifies 9 neuroticism-associated loci
Smith, D. J., Escott-Price, V, Davies, G., Bailey, M. E. S., Colodro-Conde, L., Ward, J., Vedernikov, A., Marioni, R., Cullen, B., Lyall, D., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.49 · Cited by 259
Haroon, E., Fleischer, C. C., Felger, J. C., Chen, X., Woolwine, B. J., Patel, T., Hu, X. P., & Miller, A. H. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.206 · Cited by 250
From Serotonin to Neuroplasticity: Evolvement of Theories for Major Depressive Disorder
Liu, B., Liu, J., Wang, M., Zhang, Y., & Li, L. (2017) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2017.00305 · Cited by 249
Emerging Role for Nucleus Accumbens Medium Spiny Neuron Subtypes in Depression
Francis, T. C., & Lobo, M. K. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.09.007 · Cited by 230
An astroglial basis of major depressive disorder? An overview
Wang, Q., Jie, W., Liu, J., Yang, J., & Gao, T. (2017) · Glia · doi:10.1002/glia.23143 · Cited by 222
Sanacora, G., Smith, M. A., Pathak, S., Su, H.-L., Boeijinga, P. H., McCarthy, D. J., & Quirk, M. C. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.130 · Cited by 236
Self-citationBlood microRNA changes in depressed patients during antidepressant treatment
Bocchio-Chiavetto, L., Maffioletti, E., Bettinsoli, P., Giovannini, C., Bignotti, S., Tardito, D., Corrada, D., Milanesi, L., & Gennarelli, M. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.06.013 · Cited by 238
McKlveen, J. M., Morano, R. L., Fitzgerald, M., Zoubovsky, S., Cassella, S. N., Scheimann, J. R., Ghosal, S., Mahbod, P., Packard, B. A., Myers, B., et al. (2016) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.03.2101 · Cited by 224
Stratification of astrocytes in healthy and diseased brain
Verkhratsky, A., Zorec, R., & Parpura, V. (2017) · Brain Pathology · doi:10.1111/bpa.12537 · Cited by 236
Cellular and molecular basis for stress-induced depression
Seo, J.-S., Wei, J., Qin, L., Kim, Y., Yan, Z., & Greengard, P. (2017) · Molecular Psychiatry · doi:10.1038/mp.2016.118 · Cited by 235
Page, C. E., & Coutellier, L. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.07.024 · Cited by 213
Neural correlates of change in major depressive disorder anhedonia following open-label ketamine
Lally, N., Nugent, A. C., Luckenbaugh, D. A., Niciu, M. J., Roiser, J. P., & Zarate, C. A. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114568041 · Cited by 224
Abdallah, C. G., Sanacora, G., Duman, R. S., & Krystal, J. H. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.05.010 · Cited by 219
Self-citationLaje, G., Lally, N., Mathews, D., Brutsche, N., Chemerinski, A., Akula, N., Kelmendi, B., Simen, A., McMahon, F. J., Sanacora, G., et al. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.05.031 · Cited by 213
Self-citationMatveychuk, D., Thomas, R. K., Swainson, J., Khullar, A., MacKay, M.-A., Baker, G. B., & Dursun, S. M. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320916657 · Cited by 209
The stressed synapse 2.0: pathophysiological mechanisms in stress-related neuropsychiatric disorders
Sanacora, G., Yan, Z., & Popoli, M. (2022) · Nature Reviews Neuroscience · doi:10.1038/s41583-021-00540-x · Cited by 197
Self-citationPham, T. H., & Gardier, A. M. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.02.017 · Cited by 186
Wilkinson, S. T., & Sanacora, G. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2018.11.007 · Cited by 173
Self-citationGlutamatergic Neurotransmission: Pathway to Developing Novel Rapid-Acting Antidepressant Treatments
Kadriu, B., Musazzi, L., Henter, I. D., Graves, M., Popoli, M., & Zarate, C. A. (2019) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy094 · Cited by 165
Self-citationCavalleri, L., Merlo Pich, E., Millan, M. J., Chiamulera, C., Kunath, T., Spano, P. F., & Collo, G. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.241 · Cited by 156
Pehrson, A. L., & Sanchez, C. (2014) · CNS Spectrums · doi:10.1017/s1092852913000540 · Cited by 161
( 2R,6R )-hydroxynorketamine exerts mGlu 2 receptor-dependent antidepressant actions
Zanos, P., Highland, J. N., Stewart, B. W., Georgiou, P., Jenne, C. E., Lovett, J., Morris, P. J., Thomas, C. J., Moaddel, R., Zarate, C. A., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819540116 · Cited by 152
Haroon, E., Woolwine, B. J., Chen, X., Pace, T. W., Parekh, S., Spivey, J. R., Hu, X. P., & Miller, A. H. (2014) · Neuropsychopharmacology · doi:10.1038/npp.2014.25 · Cited by 154
Gunn, B. G., Cunningham, L., Cooper, M. A., Corteen, N. L., Seifi, M., Swinny, J. D., Lambert, J. J., & Belelli, D. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.1337-13.2013 · Cited by 151
GABAA receptor-acting neurosteroids: a role in the development and regulation of the stress response
Gunn, B. G., Cunningham, L., Mitchell, S. G., Swinny, J. D., Lambert, J. J., & Belelli, D. (2015) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2014.06.001 · Cited by 149
Adding fuel to the fire: the impact of stress on the ageing brain
Prenderville, J. A., Kennedy, P. J., Dinan, T. G., & Cryan, J. F. (2015) · Trends in Neurosciences · doi:10.1016/j.tins.2014.11.001 · Cited by 136
Treccani, G., Musazzi, L., Perego, C., Milanese, M., Nava, N., Bonifacino, T., Lamanna, J., Malgaroli, A., Drago, F., Racagni, G., et al. (2014) · Molecular Psychiatry · doi:10.1038/mp.2014.5 · Cited by 133
Self-citationNicosia, N., Giovenzana, M., Misztak, P., Mingardi, J., & Musazzi, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126521 · Cited by 135
Ketamine and Beyond: Investigations into the Potential of Glutamatergic Agents to Treat Depression
Lener, M. S., Kadriu, B., & Zarate, C. A. (2017) · Drugs · doi:10.1007/s40265-017-0702-8 · Cited by 131
P2X7 Receptor Signaling in Stress and Depression
Ribeiro, D. E., Roncalho, A. L., Glaser, T., Ulrich, H., Wegener, G., & Joca, S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20112778 · Cited by 129
Carvalho, A. F., Berk, M., Hyphantis, T. N., & McIntyre, R. S. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000357500 · Cited by 123
A review of current evidence for acetyl-l-carnitine in the treatment of depression
Wang, S.-M., Han, C., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C.-U. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.02.005 · Cited by 110
Quintana, D. S., Guastella, A. J., Westlye, L. T., & Andreassen, O. A. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.166 · Cited by 107
Regulation of astrocyte glutamine synthetase in epilepsy
Eid, T., Tu, N., Lee, T.-S. W., & Lai, J. C. K. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2013.06.008 · Cited by 109
Stress-Induced Changes of Hippocampal NMDA Receptors: Modulation by Duloxetine Treatment
Calabrese, F., Guidotti, G., Molteni, R., Racagni, G., Mancini, M., & Riva, M. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0037916 · Cited by 107
Lindemann, L., Porter, R. H., Scharf, S. H., Kuennecke, B., Bruns, A., von Kienlin, M., Harrison, A. C., Paehler, A., Funk, C., Gloge, A., et al. (2015) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.114.222463 · Cited by 107
Kadriu, B., Greenwald, M., Henter, I. D., Gilbert, J. R., Kraus, C., Park, L. T., & Zarate, C. A. (2021) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyaa087 · Cited by 99
Coplan, J. D., Gopinath, S., Abdallah, C. G., & Berry, B. R. (2014) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2014.00189 · Cited by 90
Musazzi, L., Treccani, G., & Popoli, M. (2015) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2015.00060 · Cited by 83
Self-citationDoboszewska, U., Młyniec, K., Wlaź, A., Poleszak, E., Nowak, G., & Wlaź, P. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.08.013 · Cited by 81
Blunted medial prefrontal cortico-limbic reward-related effective connectivity and depression
Rupprechter, S., Romaniuk, L., Series, P., Hirose, Y., Hawkins, E., Sandu, A.-L., Waiter, G. D., McNeil, C. J., Shen, X., Harris, M. A., et al. (2020) · Brain · doi:10.1093/brain/awaa106 · Cited by 80
Imaging the effect of ketamine on synaptic density (SV2A) in the living brain
Holmes, S. E., Finnema, S. J., Naganawa, M., DellaGioia, N., Holden, D., Fowles, K., Davis, M., Ropchan, J., Emory, P., Ye, Y., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01465-2 · Cited by 78
Self-citationPozzi, L., Dorocic, I. P., Wang, X., Carlén, M., & Meletis, K. (2014) · PLoS ONE · doi:10.1371/journal.pone.0083879 · Cited by 74
Abbasi, S. H., Mohammadinejad, P., Shahmansouri, N., Salehiomran, A., Beglar, A. A., Zeinoddini, A., Forghani, S., & Akhondzadeh, S. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.04.049 · Cited by 70
Abdallah, C. G., Jackowski, A., Sato, J. R., Mao, X., Kang, G., Cheema, R., Coplan, J. D., Mathew, S. J., & Shungu, D. C. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.04.025 · Cited by 67
Glutamatergic Modulators for Major Depression from Theory to Clinical Use
McIntyre, R. S., & Jain, R. (2024) · CNS Drugs · doi:10.1007/s40263-024-01114-y · Cited by 69
Homer1/mGluR5 Activity Moderates Vulnerability to Chronic Social Stress
Wagner, K. V., Hartmann, J., Labermaier, C., Häusl, A. S., Zhao, G., Harbich, D., Schmid, B., Wang, X.-D., Santarelli, S., Kohl, C., et al. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.308 · Cited by 67
Pereira, V. S., Casarotto, P. C., Hiroaki-Sato, V. A., Sartim, A. G., Guimarães, F. S., & Joca, S. R. L. (2013) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.01.008 · Cited by 66
Jaeschke, G., Kolczewski, S., Spooren, W., Vieira, E., Bitter-Stoll, N., Boissin, P., Borroni, E., Büttelmann, B., Ceccarelli, S., Clemann, N., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501642c · Cited by 66
Millard, S. J., Weston-Green, K., & Newell, K. A. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.109908 · Cited by 62
Croarkin, P. E., Nakonezny, P. A., Husain, M. M., Melton, T., Buyukdura, J. S., Kennard, B. D., Emslie, G. J., Kozel, F. A., & Daskalakis, Z. J. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.24 · Cited by 65
Transcranial Magnetic Stimulation for Adolescent Depression
Croarkin, P. E., & MacMaster, F. P. (2019) · Child and Adolescent Psychiatric Clinics of North America · doi:10.1016/j.chc.2018.07.003 · Cited by 65
Ketamine regulates the presynaptic release machinery in the hippocampus
Müller, H. K., Wegener, G., Liebenberg, N., Zarate, C. A., Popoli, M., & Elfving, B. (2013) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2013.03.008 · Cited by 61
Self-citationHuang, P., Dong, Z., Huang, W., Zhou, C., Zhong, W., Hu, P., Wen, G., Sun, X., Hua, H., Cao, H., et al. (2017) · Behavioural Brain Research · doi:10.1016/j.bbr.2017.05.032 · Cited by 54
Kent, J. M., Daly, E., Kezic, I., Lane, R., Lim, P., De Smedt, H., De Boer, P., Van Nueten, L., Drevets, W. C., & Ceusters, M. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.01.009 · Cited by 53
The dose makes the poison: From glutamate-mediated neurogenesis to neuronal atrophy and depression
Rubio-Casillas, A., & Fernández-Guasti, A. (2016) · Reviews in the Neurosciences · doi:10.1515/revneuro-2015-0066 · Cited by 49
Esterlis, I., Holmes, S. E., Sharma, P., Krystal, J. H., & DeLorenzo, C. (2018) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.08.025 · Cited by 50
Targeting metaplasticity mechanisms to promote sustained antidepressant actions
Brown, K. A., & Gould, T. D. (2024) · Molecular Psychiatry · doi:10.1038/s41380-023-02397-1 · Cited by 49
Canbeyli, R. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15507 · Cited by 48
Huang, Z., Davis Iv, H. H., Yue, Q., Wiebking, C., Duncan, N. W., Zhang, J., Wagner, N.-F., Wolff, A., & Northoff, G. (2015) · Human Brain Mapping · doi:10.1002/hbm.22841 · Cited by 43
Fuxe, K., & Borroto-Escuela, D. O. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1074175 · Cited by 43
Hu, P., Liu, J., Yasrebi, A., Gotthardt, J. D., Bello, N. T., Pang, Z. P., & Roepke, T. A. (2016) · Endocrinology · doi:10.1210/en.2016-1191 · Cited by 40
Sensorimotor Modulation of Mood and Depression: In Search of an Optimal Mode of Stimulation
Canbeyli, R. (2013) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2013.00428 · Cited by 42
Plasticity of synapses and reward circuit function in the genesis and treatment of depression
Thompson, S. M. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-022-01422-1 · Cited by 40
Mingardi, J., La Via, L., Tornese, P., Carini, G., Trontti, K., Seguini, M., Tardito, D., Bono, F., Fiorentini, C., Elia, L., et al. (2021) · Neurobiology of Stress · doi:10.1016/j.ynstr.2021.100381 · Cited by 36
Self-citationTorres, E. R. S., Akinyeke, T., Stagaman, K., Duvoisin, R. M., Meshul, C. K., Sharpton, T. J., & Raber, J. (2018) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2018.00140 · Cited by 38
Akbar, D., Rhee, T. G., Ceban, F., Ho, R., Teopiz, K. M., Cao, B., Subramaniapillai, M., Kwan, A. T. H., Rosenblat, J. D., & McIntyre, R. S. (2023) · CNS Drugs · doi:10.1007/s40263-023-01032-5 · Cited by 38
Ahnaou, A., Ver Donck, L., & Drinkenburg, W. H. I. M. (2014) · Behavioural Brain Research · doi:10.1016/j.bbr.2014.05.003 · Cited by 31
Nava, N., Treccani, G., Liebenberg, N., Chen, F., Popoli, M., Wegener, G., & Nyengaard, J. R. (2015) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyu085 · Cited by 32
Self-citationIntrinsic Connectivity Networks of Glutamate-Mediated Antidepressant Response: A Neuroimaging Review
Demchenko, I., Tassone, V. K., Kennedy, S. H., Dunlop, K., & Bhat, V. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.864902 · Cited by 29
“Supplemented with early evidence of significantly higher plasma glutamate levels in patients with mood disorders (15), this etiological framework postulates that alterations in glutamate release, clearance, and metabolism lead to sustained accumulation of glutamate in cortical and limbic brain areas that regulate emot…”
BackgroundHutson, P. H., Tarazi, F. I., Madhoo, M., Slawecki, C., & Patkar, A. A. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.03.005 · Cited by 31
Rapastinel - an investigational NMDA-R modulator for major depressive disorder: evidence to date
Ragguett, R.-M., Rong, C., Kratiuk, K., & McIntyre, R. S. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1559295 · Cited by 30
Dadkhah, T., Rahimi-Aliabadi, S., Jamshidi, J., Ghaedi, H., Taghavi, S., Shokraeian, P., Akhavan-Niaki, H., Tafakhori, A., Ohadi, M., & Darvish, H. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.10.008 · Cited by 26
Measuring the effects of ketamine on mGluR5 using [ 18 F]FPEB and PET
Holmes, S. E., Gallezot, J.-D., Davis, M. T., DellaGioia, N., Matuskey, D., Nabulsi, N., Krystal, J. H., Javitch, J. A., DeLorenzo, C., Carson, R. E., et al. (2020) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x19886316 · Cited by 24
Pringle, A., Parsons, E., Cowen, L., McTavish, S., Cowen, P., & Harmer, C. (2012) · Journal of Psychopharmacology · doi:10.1177/0269881112446535 · Cited by 21
(2020) · Advances in Pharmacology · doi:10.1016/bs.apha.2020.04.003 · Cited by 18
The metabotropic glutamate receptor 5 as a biomarker for psychiatric disorders
(2023) · International Review of Neurobiology · doi:10.1016/bs.irn.2022.10.007 · Cited by 8
Corvo, C., Goutal, S., Mendez-David, I., Leterrier, S., Caille, F., Saba, W., Colle, R., Corruble, E., Lebon, V., Bottlaender, M., et al. (2026) · Molecular Psychiatry · doi:10.1038/s41380-025-03369-3 · Cited by 1
Metadata
- Authors
- Sanacora, G., Treccani, G., & Popoli, M.
- Affiliations
- Yale University (US)
- University of Milan (IT)
- Corresponding author
- Popoli, Maurizio
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2012-01
- Volume
- 62
- Issue
- 1
- Pages
- 63-77
- ISSN
- 0028-3908 (ISSN-L)
- PMC
- PMC3205453
- OpenAlex
- W72199885
- Cited by
- 1,036
- References
- 229
- Citations by year
- 2026: 48 · 2025: 61 · 2024: 66 · 2023: 74 · 2022: 80 · 2021: 80 · 2020: 89 · 2019: 67 · 2018: 62 · 2017: 66 · 2016: 83 · 2015: 90 · 2014: 71 · 2013: 55 · 2012: 38
- FWCI
- 6.75
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Neuropharmacology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health (R01MH081211, K02MH076222)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- depression, glutamate hypothesis, glutamatergic system, monoamine hypothesis, mood disorders, anxiety disorders, environmental stress, dendritic remodeling, synaptic loss, neuroplasticity, antidepressant mechanism, treatment-resistant depression, glutamate metabolism, limbic system
- MeSH terms
- Animals, Antidepressive Agents, Brain, Drug Evaluation, Preclinical, gamma-Aminobutyric Acid, Glucocorticoids, Humans, Synaptic Transmission, Magnetic Resonance Spectroscopy, Receptors, N-Methyl-D-Aspartate, Glutamic Acid, Mood Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
